NCT00365053 2018-06-07PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By SurgeryNational Cancer Institute (NCI)Phase 2 Completed13 enrolled 7 charts
NCT00413075 2015-07-08Study of Oral PXD101 in Patients With Advanced Solid Tumors or LymphomaValerio TherapeuticsPhase 1 Completed121 enrolled
NCT00413322 2015-07-08Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid TumorsValerio TherapeuticsPhase 1 Completed35 enrolled